Over the past eight years my research interests have been primarily connected with various aspects concerning the molecular mechanisms of action of the receptors for glucagon and insulin. At the time my work started it had only recently been appreciated that integral membrane proteins were mobile entities able to diffuse, freely within the lateral plane of the bilayer. This exciting discovery led us (Houslay et al., 1976a (Houslay et al., ,b, 1977 (Houslay et al., , 1980a and others (Schramm et al., 1977; Tolkovsky & Levitzki, 1978; Martin et al., 1979) , using independent techniques, to demonstrate that hormone receptors were able to migrate independently in the membrane lipid bilayer. Thus, activation of adenylate cyclase, mediated by the stimulatory guanine nucleotide regulatory protein N,/G, (Houslay, 1983 Gilman, 1984) , was achieved through productive collisions between these components in the plane of the bilayer. The precise nature of the complexes formed between receptors, N, and adenylate cyclase, and their 'lifetimes', appears to vary somewhat depending upon the guanine nucleotide concentration, temperature and system under study. Thus these aspects still require further definition.
That hormone-stimulated adenylate cyclases are multicomponent systems consisting of a distinct (stimulatory) receptor(s), a (stimulatory) guanine nucleotide regulatory protein (N,) and the catalytic unit of the enzyme inserted asymmetrically in the bilayer (see Houslay et al., 1980a) , prompted us to define the influence that the lipid bilayer might exert on the functioning of this information transfer system in liver plasma membranes (see Houslay Houslay, 1985~) . We were able to demonstrate that the glucagon-stimulated system, in liver plasma membranes, was strikingly sensitive to changes in the physical properties (Dipple & Houslay, 1978) and chemical composition (Houslay et al., 19766; Houslay & Palmer, 1978; Houslay et al., 1986) of the bilayer. Thus increases in bilayer fluidity were shown to activate adenylate cyclase (Dipple & Houslay, 1978; Gordon et al., 1980; Whetton et al., 1982 Whetton et al., , 1983a , whereas decreases in bilayer fluidity led to inhibition of activity Whetton et al., 1984) . Indeed, due to both the asymmetric disposition of the protein components and the asymmetry of the lipid bilayer (Whetton et al., 1982) , selective effects can be exerted on the 'resting' (basal) and 'hormone-stimulated' activity of adenylate cyclase, hence affecting the net (fold) stimulation elicited by hormone action. This is most readily appreciated by using charged, anionic (Houslay et al., 19806) and cationic (Houslay et af., 198 l) , lipophilic drugs, which perturb the two halves of the lipid bilayer selectively with appropriate selective effects on adenylate cyclase activity. We were also able to show that cholesterol optimized the functioning of adenylate cyclase in liver plasma membranes (Whetton et al., I983a,b; Houslay, 1985~) . Too high concentrations of cholesterol caused an increase in bilayer rigidity leading to inhibition, whereas if concentrations were too low then cholesterol depletion appeared to release an 'inhibitory' phospholipid species into the lipid environment interacting with adenylate cyclase and, paradoxically, decreasing the fluidity of the lipids around this enzyme. Such changes in cholesterol content and bilayer fluidity also affected the thermostability of this enzyme (Needham al., 1983a,b; Houslay, 1985~) . Too high concentrations ations in the lipid environment on adenylate cyclase activity may well have significance in disease states where membrane lipid changes occur, e.g. cirrhosis, hypercholesterolaemia and diabetes, upon alterations in dietary regimens and upon transformation, as well as a result of alterations in bilayer properties elicited by lipophilic drugs, anaesthetics and other xenobiotics. Indeed changes in vivo in membrane lipid environment with concomitant effects on adenylate cyclase functioning have been noted Vol. 14 183
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by us to occur during hibernation (Houslay & Palmer, 1978) , weaning (Dipple & Houslay, 1982) and dietary manipulation of cholesterol (Needham et al., 1985) .
More recently, however, we have been concerned with aspects of the mechanism(s) whereby insulin triggers an intracellular response. For whilst there is a good appreciation of the influence of insulin on cell physiology, until recently our understanding of the initial molecular events that occurred upon interaction of insulin with its target cell was poor (Czech, 1977; Denton et al., 1981; Houslay, 1981 Houslay, , 19843, 19853, 1986 . Insulin is basically is an anabolic hormone and, as such, affects a wide spectrum of processes within the cell. Indeed it is undoubtedly because insulin does 'so many things' that it has been very difficult to pin down any single underlying molecular mechanism which might account for its various actions. To take a case in point, insulin affects the phosphorylation state of a variety of cellular proteins. However, it is not content just to either increase or decrease the phosphorylation of specific target proteins, rather it does both. Thus insulin, for example, is seen to increase the phosphorylation state of acetyl-CoA carboxylase whilst decreasing the phosphorylation state of pyruvate dehydrogenase, i.e. it can both increase and decrease phosphorylation reactions in the cell (see Denton et al., 1981) . Nevertheless, one of the most exciting discoveries in recent times was the observation (Kasuga et al., 1982) that the insulin receptor expresses a tyrosyl protein kinase activity. The functional role of this activity has, however, still to be established as no cellular substrate, other than the receptor itself, has been identified for this activity. Indeed, receptor tryosyl kinase activity is only clearly expressed in solubilized receptor preparations, implying that it may be involved, at most, in switching on 'signalling mechanisms' in the plasma membrane itself (for reviews see Houslay, 19853, 1986) .
If one is to attempt to discern the precise molecular mechanism of insulin's various actions then, ultimately, one requires a system which can be reconsistuted with defined pure constituents and is, preferably, also amenable to genetic analysis. In the hope of being able to do this, we have chosen to investigate primarily a plasma membrane based 'model system' rather than choose to study insulin-controlled events involving cytosolic/ intracellular consistuents which are remote from the site of the insulin receptor in the plasma membrane. In choosing upon a system for study we decided that firstly it must be seen to function normally in the intact cell and secondly it should function in isolated plasma membranes, where the insulin receptors are located. By employing a system with such properties we would hope to progress to the dissection and ultimate reconstitution of the individual entities involved in insulin's generation of an intracellular signal. The system that we have chosen to investigate is that involved in the antagonism between the actions of glucagon and insulin in liver. This is achieved, primarily, through alterations in cyclic AMP concentrations. As glucagon stimulates adenylate cyclase then one might well expect to observe insulin either inhibiting this enzyme or stimulating cyclic AMP phosphodiesterase activity, the only pathway for cyclic AMP degradation in the liver (Houslay et al., 1983b . In fact insulin exerts actions on both systems (Houslay, 1981 (Houslay, , 19853, 1986 Houslay et al., 19833) .
We are not in any way suggesting that insulin exerts all of its action by decreasing the intracellular concentrations of cyclic AMP, which acts as a second messenger for a variety of hormones including glucagon. Rather, we would like to suggest that insulin exerts perhaps certain of its actions through control of cyclic AMP concentrations and that the opportunity of examining the mechanism whereby it does this might well shed light on signal generation by the insulin receptor itself. As a model system we have thus chosen to investigate hepatocytes, where insulin can antagonize the action of glucagon in stimulating glycogenolysis and gluconeogenesis.
Insulin and glucagon can regulate hepatocyte intracellular cyclic AMP concentrations
We (Heyworth et al., 1983a) and others (Blackmore et al., 1979; Pilkis et al., 1985) have shown that insulin can decrease hepatocyte intracellular cyclic AMP concentrations that have been elevated by exposure of the cells to glucagon. This action appears to be exerted through high-affinity insulin receptors as it exhibits an EC,, of 0.4nM. The precise kinetics of this response are clearly affected according to whether insulin was added just before, at the same time or just after the addition of glucagon (see Fig. 1 ). This, as we shall see later, is due to complex interactions between processes triggered by the cell-surface receptors for these two hormones. 
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In hepatocytes, cyclic AMP concentrations are determined by the activity of the plasma membrane enzyme, adenylate cyclase (synthetic pathway), and also by a family of cyclic AMP phosphodiesterases (degradative pathway). Cyclic AMP exit from the cell is small and is not regulated by hormone action in hepatocytes . One can assess the magnitude of any action of insulin on the synthetic and degradative enzyme pathways by employing the non-specific, reversible cyclic AMP phosphodiesterase inhibitor isobutylmethylxanthine (IBMX). Used at concentrations of 1 mM it will inhibit over 90% of the cyclic AMP phosphodiesterase activity expressed in hepatocyte homogenates.
Under basal conditions the flux through the cyclic AMP pathway, in intact hepatocytes, is relatively small. Thus blockade of cyclic AMP phosphodiesterase activity using either IBMX or RO-1724 will cause, at most, a doubling of basal cyclic AMP concentrations (resting levels at approx. 1 p~) over a 2@-30min incubation period at 37°C . Other cells, e.g. adipocytes, can respond differently to phosphodiesterase inhibitors which cause a rapid rise in intracellular cyclic AMP if 'relatively' high rates of synthesis and degradation are occurring.
Intriguingly, when hepatocytes were treated with glucagon concentrations of 10 nM and above, any action of insulin in decreasing intracellular cyclic AMP concentrations was totally obliterated in the presence of IBMX . Under such conditions then, one can conclude that insulin was exerting its effect predominantly by increasing cyclic AMP phosphodiesterase activity rather than by any inhibitory effect on adenylate cyclase activity. However, at physiological concentrations of glucagon (0.14.5 nM), only about half of the inhibitory effect of insulin could be obliterated by IBMX . From these studies, using intact hepatocytes, we can conclude that insulin can exert actions through both inhibiting adenylate cyclase as well as by stimulating cyclic AMP phosphodiesterase activity (Fig. 2) but that the relative magnitude of insulin's ability to modulate these two processes is regulated by the concentration of glucagon. Vol. 14 Inhibition of adenylate cyclase activity in isolated liver plasma membranes by insulin Insulin can, in a dose-dependent fashion (EC,, 0.1 nM), inhibit adenylate cyclase activity by between 20 and 30% in plasma membranes isolated from either hepatocytes or liver (Heyworth & Houslay, 1983b; A. M. Grey, D. Gawler & M. D. Houslay, unpublished work) . This action is completely dependent upon the presence of GTP in the assays (EC,, 3 p~) , is enhanced by Na+ and is obliterated when Mn2+ replaces Mg2+ in the assays.
Intriguingly, the ability of insulin to inhibit adenylate cyclase, in isolated membranes, was blocked competitively by glucagon in a dose-dependent fashion with an EC,, of 1 nM. This observation thus correlates completely with that seen using intact hepatocytes, where insulin only exerted an inhibitory effect on cyclic AMP production (adenylate cyclase activity) at low glucagon concentrations (before the onset of glucagon desensitization/ selective 'insulin-resistance', see below) (Heyworth & Houslay, 1983b) .
It is of interest that the EC,, for the action of glucagon in abolishing the inhibitory effect of insulin on adenylate cyclase, in isolated plasma membranes, is identical to that observed for the stimulation of adenylate cyclase by glucagon as well. However, insulin and glucagon both bind to distinct receptors and the binding of insulin does not appear to be affected by glucagon and vice versa. This suggests that the competitive action must be at a post-receptor level involving components of the signalling mechanism itself. Now, occupied glucagon receptors activate adenylate cyclase through a well-defined mechanism (Gilman, 1984; Houslay, 1984a ) involving a distinct, stimulatory, guanine nucleotide regulatory protein called N, (or G,). This protein consists of a distinct a-subunit (a-N,) complexed together with a /?-and a y-subunit (Gilman, 1984) .
The sequence which leads to adenylate cyclase activation may be written as follows:
(2) N,-a* then activates adenylate cyclase (3)
In this scheme HR refers to the occupied glucagon (hormone)-receptor complex, and * signifies an activated state. This GTP-dependent process depends upon the dissociation of N,* to release a free activated (a-N,*)-subunit which activates adenylate cyclase. De-activation of a-N: is believed to ensue as a result of GTP hydrolysis with subsequent re-association with the (Ply) complex (Fig. 3) .
Receptor-mediated inhibition of adenylate cyclase is elicited by a number of ligands including, for example, somatostatin, opiates and a,-adrenergic agonists. These function through a distinct guanine nucleotide regulatory protein called N, (or Gi) . This species has a distinct a-subunit complexed together with a y-subunit and with a /?-subunit which is identical to that found associated with N,. Occupied receptors for 'inhibitory' hormones thus trigger the dissociation of Ni, by a process analogous to those describes in eqns.
(1) and (2), to yield an activated a-Nrsubunit and release the /? and y components. Ni also expresses a GTPase activity.
Inhibition of adenylate cyclase is perceived as being mediated by Ni through two distinct pathways. Firstly, upon Ni activation, the released /?-subunit, found in common with N,, will inhibit, by mass action, N, dissociation and activation (see Gilman, 1984; Houslay, 1984~) . The degree of inhibition elicited through this route will clearly be affected markedly by the degree of occupancy of the stimulatory receptors as well, which will also determine the degree of N, dissociation. Indeed one might expect that inhibitory hormones working through such a route would express an apparently competitive inhibitory action, the degree of inhibition observed being dependent upon a variety of factors such as the level of occupancy of inhibitory and stimulatory receptors, the relative amounts of Ni and N,, their affinity for b-subunits and so on. Secondly, the activated a-subunit of Ni is seen as exerting a direct inhibitory effect upon the catalytic unit of adenylate cyclase itself (see Houslay, 1984a; Birnbaumer et al., 1985) . Whether a-NTcompetes with a-Na for a common site on adenylate cyclase or there are distinct regulatory sites for these two components remains to be seen.
The structural and functional identification of both N, and Ni owes a considerable amount to two bacterial exotoxins. Cholera toxin causes the NAD+-dependent ADP-ribosylation of the a-subunit of N, (Van Heyningen, 1977; Gillman, 1984; Houslay, 1984~) . This process also depends upon GTP and leads to the activation and dissociation of N, into its constituent subunits. It is believed that cholera toxin inhibits an inherent GTPase activity associated with a-N,, hence allowing it to remain activated. In contrast, pertussis toxin ADP-ribosylates the a-subunit of Ni but, in this instance, it blocks the dissociation and activation of this regulatory protein and this obliterates inhibitory responses (Gilman, 1984) .
We can show that the treatment of hepatocytes with pertussis toxin completely obliterates the ability of insulin to inhibit adenylate cyclase in both intact hepatocytes and in membranes isolated from pertussis toxintreated cells (Heyworth et al., 1986) . Based upon evidence from a number of systems that pertussis toxin blocks inhibitory effects upon adenylate cyclase through a ribosylation of Ni (see Gilman, 1984; Birnbaumer et al., 1985) , one might reasonably make the suggestion that insulin exerts effects through the guanine nucleotide regulatory protein system in liver plasma membrane, in particular, that insulin exerts actions through Ni.
The mechanism whereby insulin exerts its function would most logically be through the release of the 'common' b-subunit from the guanine nucleotide regulatory protein complex. This would readily account for the diminishing inhibitory effect of insulin, on adenylate cyclase activity in broken plasma membranes, that is observed as glucagon concentration are raised, providing a greater stimulus for N, dissociation. Support for such a 'b-subunit inhibitory model' comes from our observations (A. M. Grey & M. D. Houslay, unpublished work) that insulin, in a dose-dependent fashion, increased the characteristic lag time for activation of adenylate cyclase by low concentrations of the non-hydrolysable GTP analogue guanylyl-5'-imidodiphosphate (p[NH]ppG).
As pmH]ppG activation of adenylate cyclase is due to the activation and dissociation of N,, then one might well predict that insulin would inhibit this process by releasing 'p subunits from either Ni or, as we have suggested , an insulin-specific guanine nucleotide regulatory protein called Nins (see below).
What, however, might appear to be inconsistent with insulin exerting its effects through Ni is that cholera toxin treatment of hepatocytes, which activates N, , also blocks the inhibitory effect of insulin . This action is in contrast with other systems where inhibitory effects exerted through Ni were still observed in cholera toxin-treated cells (see, e.g., Aktories et al., 1982; Murayama & Ui, 1983) . Alternative explanations might therefore be that insulin either inhibits N, dissociation, perhaps by modifying (phosphorylating) one of the constituent subunits of N,, or that insulin exerts actions through a distinct species of guanine nucleotide regulatory protein. These alternatives will be developed later on in this review.
One should note, however, that insulin's inhibitory effect on adenylate cyclase is relatively small, 2&30% at most, and a number of conditions serve to reduce it still further. Thus concentrations of insulin greater than 1 0 -8~ show a diminishing effect, i.e. like a number of insulin's actions a 'bell-shaped' dose-response curve is observed; high gluagon (stimulatory ligand) competes the effect out, glucagon desensitization obliterates the effect and GTP is required for the effect. Clearly then care must be taken in performing the experiments. One other point of caution is that a number of adenylate cyclase assays utilize a pool (approx. 1 mM) of unlabelled cyclic AMP to 'trap' the labelled cyclic AMP formed by adenylate cyclase. As high cyclic AMP concentrations appear to diminish insulin receptor functioning then it is possible that this too might reduce the inhibitory action of insulin on adenylate cyclase in broken membrane studies.
Insulin activates distinct cyclic A M P phosphodiesterases in intact hepatocytes
Cyclic AMP phosphodiesterase occurs in multiple forms within the hepatocyte, being found in both membrane and cytosol (soluble) fractions. We have identified distinct species in plasma membrane (Marchmont & Houslay, 1980a) , endoplasmic reticulum (Cercek et al., 1983; , mitochondria1 (Cercek & Houslay, 1982) and cytosol fractions (Marchmont & Houslay, 1980a ; N. Pyne & M. D. Houslay, unpublished work) . However, little cyclic AMP phosphodiesterase activity is found in either the Golgi or lysosomal fractions (Cercek & Houslay, 1982; Cercek et al., 1983) .
Often, when cyclic AMP phosphodiesterase activity is measured in cyclic membrane fractions, 'high-speed' supernatants or in homogenates, it is misleadingly categorized into 'high-K,' and low-K,' activities. This grossly oversimplifies a very complex situation where a variety of distinct enzymes exist all exhibiting rather different kinetics (see Houslay et al., 1983b) . It is more than likely that the enzymes found exhibiting extremely high K, values (mM range) towards cyclic AMP, e.g. in the mitochondrion (Cercek & Houslay, 1982) , actually utilize another substrate in situ in the cell. That still leaves a variety of 'low-affinity' enzymes, for example, the Ca*+-calmodulin-regulated enzyme, exhibiting K, values in the I C L I O O~M range, which are found associated with various membrane and cytosol fractions. In addition one finds very distinct high-affinity enzymes exhibiting K, values below 1 0~~. These appear to fall into at least two categories. Firstly, there are distinct species demonstrating apparent negative co-operativity, e.g. the peripheral rat liver plasma membrane enzyme , 1982) , examples of which we have purified to apparent homogeneity from both liver cytosol and plasma membranes (Pyne et al., 1986 ). One is immediately struck then by the existence of a diverse array of cyclic AMP phosphodiesterases in hepatocytes, as well as other cells. Each of these enzymes, in hepatocytes, is potentially capable of metabolizing cyclic AMP over the range of concentrations, from 1 to 20 p~, depending upon the degree of stimulation of adenylate cyclase by glucagon, likely to be encountered physiologically. The question remains then as to whether each enzyme is involved in 'total' hepatocyte cyclic AMP metabolism or whether distinct compartments/pools exist which are controlled by particular species. We are trying to assess the functional importance of these species by the use of selective activation by hormones, selective inhibition by specific inhibitors and genetic analysis.
In order to assess the ability of various hormones in regulating cyclic AMP phosphodiesterase activity in intact cells, we have developed a rapid subcellular fractionation technique employing a self-generating Percoll gradient. This was designed to separate out all of the cellular membrane fractions on a single gradient in order to assess cyclic AMP phosphodiesterase activation rapidly. A crucial feature of this procedure was that adequate separation of the various cellular membranes was achieved, otherwise activation of a particular phosphodiesterase in a specific fraction might well be obscured by significant amounts of the activity of other membrane phosphodiesterases which are not activated by hormones (Heyworth et al., 1983a) .
Treatment of hepatocytes with insulin (10 nM) can be seen, upon 'Percoll gradient analysis', to lead to the activation of two distinct cyclic AMP phosphodiesterases. These are a plasma membrane enzyme and an enzyme associated with an intracellular vesicle fraction, which we have called the 'dense-vesicle' enzyme (Heyworth et al., 1983a) .
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The plasma membrane enzyme has been purified to apparent homogeneity and shown to be a 52kDa monomer (Marchmont et al., 1981) al., 1983a) ; this is despite it being a peripheral protein, associated with the cytosol surface of the plasma membrane through ionic interactions, rather than binding through hydrophobic interactions as do integral enzymes. The peripheral phosphodiesterase does not partition between various intracellular membranes as it binds to a single species of integral plasma membrane protein ) that serves to localize it. At present we do not know the identity of this integral plasma membrane protein but irradiation inactivation experiments (Houslay et al., 19836,~) suggest that it either is or has a 90kDa component. The sites that it provides on the plasma membrane, for the peripheral phosphodiesterase, appear to be fully occupied with this enzyme and approximate, in number, those of the insulin receptor itself (Houslay & Marchmont. 198 1) .
The 'dense-vesicle' enzyme, unlike the peripheral plasma membrane phosphodiesterase, is activated by exposure of hepatocytes to both insulin and glucagon (Heyworth et al., 1983a) . This enzyme can be isolated by 'hypotonic shock' treatment of an appropriate membrane fraction (Wilson et al., 1983 ) and appears to be identical with the species noted by others previously (Loten & Sneyd, 1970; Loten et al., 1978) . This is an integral enzyme, which can be released with little apparent change in activity upon 'hypotonic shock' treatment' of the membrane fraction. species, where activation elicited by either insulin or glucagon is still appparent. The 'hypotonic-shockreleased' enzyme is also a high-affinity species, with a K , of 5 p~, displaying kinetics indicative of apparent negative co-operativity. We (M. D. Houslay, N. Pyne & M. Cooper, unpublished work) have now purified this solubilized enzyme to apparent homogeneity and shown it to be a 110 kDa dimer, with sodium dodecyl sulphate/ polyacrylamide-gel electrophoresis identifying two subunits of 5 1 and 57 kDa. However, iodinated tryptic peptide two-dimensional maps of these two subunits has indicated that there is a very close homology between these two species. One interpretation of this is that they are both proteolytic fragments derived from the same parent molecule where a proteolytic event, leading to solubilization, occurred at one of two sites which were fairly close to each other. We have now raised antibodies against the purified 'hypotonic-shock-solubilized' enzyme, which have been used to identify the 'native' enzyme that is present in the membrane. This 'native' species can be solubilized using detergents in the presence of protease inhibitors, and upon Western blotting appears to have a single 63 kDa component. This suggests that the 51 and 57kDa components are both derived from the same parent (native) subunit of 63 kDa, which probably forms a dimer in the membrane.
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The 'dense-vesicle' enzyme is totally dissimilar to the plasma membrane enzyme as regards M , , association with the membrane, peptide mapping and immunological identity. Indeed, antibodies against the plasma membrane enzyme do not react with the 'dense-vesicle' enzyme either (M. D.Houslay, M. Cooper & N. Pyne, unpublished work).
Activation of the 'dense-vesicle' enzyme can be elicited by glucagon and this effect is mimicked by raising intracellular cyclic AMP concentrations, implying that a cyclic AMP-dependent phosphorylation event may be involved. We can now show that the purified enzyme is indeed a substrate for the purified catalytic unit of cyclic AMP-dependent protein kinase and, furthermore, that a phosphorylated enzyme can be immunoprecipitated from hepatocytes treated with 32 P and stimulated by glucagon.
The mechanism whereby insulin activates the 'densevesicle' enzyme is not known. However, insulin would appear to activate the two phosphodiesterases by distinct processes, as activation of the 'dense-vesicle' enzyme can be blocked using lysosomotropic agents, lowering intracellular ATP concentrations and lowering the incubation temperature to 20°C. Based upon these observations we have suggested ) that a membraneprocessing or membrane-translocation process plays a crucial role in the activation process of the 'dense-vesicle' enzyme. Indeed, it may be that insulin instigates the translocation of this phosphodiesterase in a process in which an 'inactive' form of the phosphodiesterase migrates to the 'dense-vesicle' location, where it is subsequently activated. We (Heyworth et al., 1986) , in hepatocytes, and others, in adipocytes (Elks et al., 1983) , have shown that pertussis toxin treatment of intact cells blocks insulin's activation of this enzyme. This might indicate either the direct involvement of a guanine nucleotide regulatory protein, such as Ni, or the indirect involvement of a guanine nucleotide regulatory protein controlling a secretory/ Ca2+ -dependent mechanism. The latter interpretation would be in accord with our earlier observations .
Neither glucagon nor elevated cyclic AMP concentrations elicit the activation of the peripheral plasma membrane enzyme. However, increased cyclic AMP concentrations do potentiate the stimulatory effect of insulin on this enzyme in intact hepatocytes. In this light it was deemed rather surprising that treatment of hepatocytes with cholera toxin actually elicited the activation of the peripheral plasma membrane phosphodiesterase . This clearly could not be due to the increase in cyclic AMP concentrations caused by the activation of N,, and hence adenylate cyclase, by cholera toxin. Indeed, the addition of insulin to cholera toxintreated cells elicited no further increase in activation of this phosphodiesterase, implying that insulin and cholera toxin might achieve their effects by a common mode of action.
One possible explanation for this action of cholera toxin is that a guanine nucleotide regulatory protein, other than N,, is involved in mediating the activation of this particular phosphodiesterase. Indeed, there is a precedent for such a suggestion as rhodopsin catalyses the activation of a cyclic GMP phosphodiesterase in retinal rods through a distinct guanine nucleotide regulatory protein called transducin (Bitensky et al., 1982) , which is a substrate for both cholera and pertussis toxins (see Gilman, 1984) . In hepatocytes, it is clear that N, cannot be responsible for activating the peripheral phosphodiesterase as glucagon activates N, yet does not activate this enzyme. Furthermore, Ni is not involved as pertussis toxin treatment of hepatocytes does not affect the ability of insulin to activate this enzyme (Heyworth et al., 1986) . Thus, if a guanine nucleotide regulatory protein is involved in the activating mechanism of this enzyme it is distinct from both N, and N, yet it is a substrate for, and is activated by, cholera toxin .
A selective 'insulin-resistant ' state is induced by glucagon treatment of hepatocytes Exposure of hepatocytes to glucagon leads to transient elevation in intracellular cyclic AMP (see Fig. 1 ) and it also activates the 'dense-vesicle' phosphodiesterase. In contrast, a 5 min pretreatment of intact hepatocytes with glucagon completely obliterates the ability of insulin to activate the peripheral plasma membrane phosphodiesterase. This process is dose-dependent upon glucagon with an EC, of 0.1 nM. Intriguingly, this effect, unlike glucagon's activation of the 'dense-vesicle' enzyme, is not mimicked by cyclic AMP. Indeed the EC for this 'blockade-process' occurs at a concentration o?glucagon which is an order of magnitude lower than that which elicits adenylate cyclase activation (Heyworth et al., 1983a) . As two distinct sub-populations of glucagon receptors have been observed in liver membranes (Corvera et al., 1984; Musso et al., 1984) , it is possible that glucagon initiates this 'insulin-resistant' state through a set of high-affinity receptors which are distinct from those which activate adenylate cyclase through N, . The process by which glucagon elicits this selective 'insulin-resistant' state bears a remarkable similarity to that whereby glucagon causes desensitization in hepatocytes : glucagon pretreatment of hepatocytes causes the time-and dose-dependent desensitization of glucagon-stimulated adenylate cyclase to occur through a process which, like the induction of selective 'insulinresistance' is also cyclic AMP-dependent, shows a relatively slow time-dependence, taking 5 min to achieve a maximal effect, and shows an identical dose-dependence (Heyworth & Houslay, 1983a; . One might expect that glucagon-desensitization might be due to a modification of one of the adenylate cyclase components such as the glucagon receptor, N, and the catalytic unit of adenylate cyclase. The catalytic unit appears not to be affected directly as the forskolinstimulated and basal activities were unchanged. As glucagon binding was unaffected and there was no loss of plasma membrane glucagon receptors, this indicated that receptor functioning was normal as well. Thus the lesion appears to be at the level of regulation by guanine nucleotides. Consistent with this interpretation are our observations that the expression of desensitization in plasma membranes from glucagon-treated hepatoc tes could be overcome by using Mn2+ instead of Mg" in adenylate cyclase assays or by elevating Mg2+ concentrations, the actions of which are known to enhance the functioning of N, (see Birnbaumer, 1985; . Furthermore, glucagon desensitization led to changes in the lag time for activation of adenylate cyclase by the non-hydrolysable GTP analogue p[NH]ppG and also blocked the activation of adenylate cyclase by isoprenaline when hepatocytes from young animals were used. All of these data suggest that glucagon desensitization triggers a process which diminishes the functioning of N,. This might be effected by the indirect activation of N,, elicited by glucagon, as glucagon-densensitization can be blocked by pertussis toxin .
We have suggested that insulin tnight exert its action on adenylate cyclase and on the peripheral cyclic AMP Exposure of hepatocytes to glucagon blocks certain of insulin's actions through a cyclic AMP-independent process. This is seen in both hepatocytes and adipocytes. We have suggested that this action blocks insulin's interaction with guanine nucleotide regulatory protein system and might, if triggered pathologically, offer an explanation for insulin-resistant diabetes.
phosphodiesterase through a distinct guanine nucleotide regulatory protein which we have called N,,, . Now, glucagon pretreatment of hepatocytes blocks insulin's ability to both inhibit adenylate cyclase and to activate the peripheral cyclic AMP phosphodiesterase . It is thus tempting to suggest that whatever process underlies glucagon desensitization, where N, functioning is inhibited, also blocks N,,, functioning (Fig. 4) . One can now appreciate that the underlying complexity of interaction between receptormediated processes triggered by both glucagon and insulin, means that both the order of exposure of insulin and glucagon to hepatocytes and their relative concentrations can make for very different effects as far as cyclic AMP responses are concerned .
Our contention that glucagon desensitization and the glucagon-mediated 'insulin-resistant' state processes are closely connected is supported by our observations that (i) adenosine functioning through a high-affinity 'R-type' receptor , (ii) the tumourpromoting agent 12-0-tetradecanoylphorbol 1 3-acetate (TPA) (Heyworth et al., 1984c (Heyworth et al., , 1985b , (iii) pertussis toxin (Heyworth et al., 1984a) and (iv) the Ca2+ ionophore A23178 ( S . R. Wilson, C. M. Heyworth & M. D. Houslay, unpublished work) all prevent both the expression of glucagon desensitization and the glucagon-induced block on insulin's ability to activate the peripheral cyclic AMP phosphodiesterase (selective insulin-resistance). In such pretreated cells, therefore, insulin can actually activate the plasma membrane phosphodiesterase in the presence of glucagon.
If certain of insulin's actions do indeed involve a distinct guanine nucleotide regulatory protein then its functioning would appear to be affected by the process which elicits glucagon-desensitization.
Evaluation of the relative functional SignlJcance of activation of speciJic hepatocyte cyclic AMP phosphodiesterases by insulin After 5 min exposure of hepatocytes to glucagon (10 nM) the cyclic AMP concentrations have reached a peak from which they slowly decline (Fig. 1) . The addition of insulin at the 'peak point' (5min after glucagon) causes cyclic AMP concentrations to reach basal levels at over double the rate observed in the absence of insulin (Heyworth et al., 1983b) . Under these conditions of 'high' glucagon concentrations the action of insulin is entirely due to phosphodiesterase activation as it can be totally obliterated by the phosphodiesterase inhibitor IBMX (1 mM). This is because, firstly, the high glucagon concentrations (1 0 nM) ensure high receptor occupany, eliciting, intially, full N, activation which competes out any inhibitory action of insulin on adenylate cyclase (vide supra). Secondly, the resultant glucagon-desensitized state would, in itself, ensure that insulin could not now exert any inhibitory action on the 'residual' adenylate cyclase activity as it induces 'selective insulin resistance'. Now, the glucagon-induced state of selective 'insulinresistance' would also have prevented activation of the plasma membrane phosphodiesterase by insulin. This implies that insulin's entire 'phosphodiesterase' effect in lowering cyclic AMP concentrations, that is noted under these circumstances, should be due to activation of the 'dense-vesicle' enzyme. We can test this hypothesis by obliterating insulin's stimulation of the 'dense-vesicle' enzyme either by using lysosomotropic drugs or by using fructose to deplete intracellular ATP. Surprisingly, these actions failed to either prevent or inhibit the ability of insulin to decrease those cyclic AMP concentrations elevated by glucagon (Heyworth et al., 1984b) . This suggests that there is a third cyclic AMP phosphodiesterase which is activated by insulin in a manner which is rapidly reversed, as it was not observed by Percollgradient analysis. Activation could be due to a soluble substance which is diluted upon gradient analysis and subsequent assay or an inherent instability in the modification which causes the activation (see Houslay, 1985b) . What is this enzyme? The two other major species of cyclic AMP phosphodiesterase activity in the liver are the Caz+ xalmodulin-activated enzyme and the cyclic GMPactivated cyclic AMP phosphodiesterase. The former enzyme is an unlikely candidate as insulin antagonizes the actions of hormones such as vasopressin, angiotensin and c1, -adrenergic agonists which result in an increase in the presumptive activator, cytosolic Ca2+. Another alternative is that it is the cyclic GMP-activated cyclic AMP phosphodiesterase which is activated by insulin. Indeed, our preliminary experiments employing selective inhibitors suggest that this may well be the target enzyme. However, the mechanism by which this enzyme is activated by insulin most certainly does not involve any insulin-stimulated rise in cyclic GMP concentrations, for we have not observed any significant sustained rise in intracellular cyclic GMP concentrations after exposure of hepatocytes to insulin, which would be necessary to yield activation of this enzyme (F. Irvine & M. D. Houslay, unpublished work). The detailed identification of this third insulin-regulated species and its mechanism of activation require further study.
The ability to activate the plasma membrane phosphodiesterase selectively will allow us to evaluate its ability to regulate intracellular cyclic AMP concentrations. Now insulin can be allowed to activate this enzyme in hepatocytes which have been exposed to glucagon if one pretreats them with adenosine or its non-metabolizable analogue, N6-phenylisopropyladenosine. When this is done, then the rate at which insulin decreases glucagonelevated cyclic AMP concentrations is in fact doubled (Heyworth et al., 19846) . This indicates that the plasma membrane phosphodiesterase has the ability to exert Vol. 14 The action of cholera toxin and the identiJication of putative N,, Cholera toxin causes the activation and dissociation of N, by eliciting the NAD+-dependent ADP-ribosylation of its cr-subunit (Van Heyningen, 1977; Gilman, 1984) . In hepatocytes this leads to the activation of adenylate cyclase and an increase in intracellular cyclic AMP concentrations (Houslay & Elliott, 1979 , 1981 . Thus cholera toxin would be expected to, and indeed does, activate the 'dense-vesicle' phosphodiesterase by mimicking the action of glucagon . What is intriguing is that cholera toxin also activates the plasma membrane phosphodiesterase through a cyclic AMP-independent process: this not being mimicked by dibutyryl cyclic AMP . As insulin does not result in any further activation of this enzyme after cholera-toxin treatment of cells it is possible that they might share the same activation mechanism. Clearly, N, activation per se will not activate this enzyme as exposure to glucagon alone, which activates N,, does not stimulate this enzyme. Our suggestion is that the putative Nins is a substrate for cholera toxin-mediated ribosylation which leads to Nins activation. Such an explanation is also consistent with the failure of insulin to inhibit adenylate cyclase in membranes from cholera toxin-treated cells . In such instances we would expect full activation of both N, and the putative Nins to have occurred with the consequent insensitivity of adenylate cyclase to both activation by glucagon or inhibition by insulin, a net activation being expected if [N,] is greater In plasma membranes from liver and other cells cholera toxin has been shown to cause the NAD+-dependent ADP-ribosylation of the 45 kDa a-subunit of N, (Gilman, 1984) . However, a number of other proteins also appear to be ribosylated, some of which appear to be high-affinity GTP-binding proteins (see Heyworth et al., 1985~) . Activation of guanine nucleotide regulatory proteins causes changes in the conformation of the cr-subunits leading to altered susceptibility to proteolysis and ribosylation (see Hudson et al., 1981; Heyworth et al., 1985~) . If insulin causes the activation and dissociation of Nins it is possible that the ability of the activated a-subunit of Nins to be ribosylated by cholera toxin might be altered upon activation by insulin. Indeed we (Heyworth et al., 1985a) have shown recently that the cholera toxin-mediated ribosylation of a 25 kDa subunit in rat liver membranes was inhibited by insulin (Fig. 5) whilst the ribosylation of other proteins, including N,, was not. Furthermore, using a~ido-[~~PlGTP as a photoaffinity label, we were also able to identify a high-affinity GTP-binding protein of similar molecular mass. It is tempting to assign this 25 kDa species to the putative Nins. Consistent with such an interpretation are our observations that (i) the action of insulin in decreasing the cholera toxin-catalysed ribosylation of this species was reduced in membranes from glucagon-treated (desensitized/insulin-resistant) cells; that (ii) the ability of cholera toxin to both ribosylate this species and to activate the plasma membrane phosphodiesterase was reduced by treatment of the cells with pertussis toxin, and that (iii) the tumour-promoting agent TPA both inhibited cholera toxin-catalysed ribosylation of the 25 kDa species exclusively and also inhibited the cholera toxin-catalysed activation of the peripheral phosphodiesterase (Heyworth et al., 19856) .
Action of pertussis toxin
Pertussis toxin causes the ADP-ribosylation of the 40kDa a-subunit of Ni in liver plasma membranes (Gilman, 1984; Heyworth et al., 1984~) . This prevents Ni activation/dissociation and hence blocks inhibitory responses on adenylate cyclase being expressed.
Treatment of hepatocytes with pertussis toxin does not prevent insulin's stimulation of the plasma membrane phosphodiesterase (less than 5% effect) although it does block the inhibitory action of insulin (greater than 90% block) upon adenylate cyclase. This is the only piece of evidence that we have obtained which appears to indicate that insulin might exert its effect on the peripheral cyclic AMP phosphodiesterase and on adenylate cyclase by distinct mechanisms, for these experiments with pertussis toxin indiate that insulin might inhibit adenylate cyclase through Ni . Could there be an alternative explanation to the conclusion that insulin exerts its inhibitory action on adenylate cyclase through N,? One possibility is that pertussis toxin prevents insulin inhibiting adenylate cyclase through an indirect action. Here it is envisaged that excess Ni a-subunits, free of B / y complexes, provide, upon their ribosylation by pertussis toxin, a high affinity 'sink' for P-/y-subunits released from N,,,. This might be expected to obliterate insulin's inhibitory effect upon adenylate cyclase if this were achieved through a B-subunit inhibitory mechanism (Fig. 6) .
Concluding remarks
Despite the frustrations of dealing with such a complex system it would appear to be important to pursue an approach using isolated membranes in order to define the various components involved in this particular activation mechanism.
Insulin and glucagon have long been thought to antagonize each others actions merely through control of intracellular cyclic AMP concentrations in the cytosol. We now see that there is a subtle interplay between regulatory systems coupled to these receptors in the plasma membrane. This is not only highlighted by our own studies but also by others studying insulin-stimulated glucose transport in adipocytes. In that instance glucagon and catecholamines can inhibit insulin's stimulation of glucose transport by both cyclic AMP-dependent and -independent mechanisms (see Houslay 19856 for review).
Vol. 14 Pertussis toxin blocks the inhibitory effect of insulin on adenylate cyclase. This might indicate that insulin can exert certain of its effects through N,. However, it is possible that insulin might exert inhibitory actions through a putative N,,, which, whilst not a substrate for pertussis toxin, could be blocked by an indirect action.
The parallel between our studies is particularly acute as regards the cyclic AMP-independent mechanisms as, in both instances, adenosine prevents the expression of an 'insulin-resistant' state. In the case of insulin-stimulated glucose transport the blockade exerted by catecholamines/ glucagon is not directed towards recruitment of carriers to the plasma membrane but rather towards the process by which carrier activation is achieved in the plasma membrane itself. It is thus tempting to suggest that the plasma membrane-located mechanism for carrier activation is identical to that by which insulin elicits activation of the plasma membrane phosphodiesterase. Certainly one of the most interesting outstanding problems that we have centres on the molecular mechanism whereby glucagon elicits desensitization and the onset of a selective 'insulin-resistant' state. That such a mechanism may be triggered pathologically might well offer an explanation for instances of maturity onset (insulinresistant) diabetes.
All of our data imply that the insulin receptor exerts its actions upon cells by proliferation of a signal at the level of the receptor (Fig. 7) . Part of this appears to arise through receptor endocytosis and processing, part by interaction with the guanine nucleotide regulatory protein system. Whether the primary trigger for both events is the tyrosyl kinase activity associated with the receptor remains to be seen (see Houslay, 19856, 1986) . In this respect it is intriguing that the ras oncogene product, a 21-23 kDa high-affinity GTP-binding protein, has been shown to interact with the epidermal growth factor and possibly also the insulin receptor (Kamata & Feramiso, 1984) , leading to a concomitant change in kinase activity. Whether the putative Nins is related to this protein and whether Nins can affect kinase activity remains to be seen. Certainly the tyrosyl kinase activity attributed to solubilized insulin receptor is not A 'multipathway ' mechanism for insulin's action The insulin receptor is envisaged as a tyrosyl protein kinase that, by interaction with other plasma membrane protein components, generates an array of signals which emanate from the plasma membrane. It is this very diversity which might account for the variety of actions that insulin exerts on its target cells.
nearly as evident in intact membranes. This might imply that membranes contain a regulatory system interacting with the insulin receptor. In preliminary experiments we have been able to demonstrate in placental plasma membranes that p[NG]ppG can mimic insulin's action in stimulating the phosphorylation of the insulin receptor. Thus a variety of experiments indicate that the insulin receptor can interact with the guanine nucleotide regulatory protein system in plasma membranes. This should provide an intriguing system for further study on the interactions between the insulin receptor and other plasma membrane proteins.
Whether the insulin receptor, or a component of its signalling apparatus, has an oncogene equivalent as per the epidermal growth factor receptor is another possibility to be pursued in relation to the growth promoting properties that insulin exhibits.
